Jyoti Clinical and Pathological Laboratory
Shirpur, Maharashtra, 425 405, India
NCT Number: NCT00940251
To determine the safety and efficacy of an Ayurvedic formulation, Mersina in type 2 diabetic patients with secondary failure to oral hypoglycemic agents, a randomized double blind, single centre, study of 3 months duration was carried out.
Looking for future studies?
Notify Me30 year–60 year
All sexes
Interventional
Phase 2
Shirpur, Maharashtra, 425 405, India
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Secondary failure to Oral Hypoglycemic Agents was diagnosed if the patient had HbA1c levels > 8.5% even after supplementation of maximal dose of a combination of a sulphonylurea (15 mg glybenclamide or 160 mg gliclazide or 15 mg glipizide) and metformin 1500 mg/day.
Exclusion criteria
Patients with ketosis, diabetes related complications, hepatic or renal disease, pancreatitis, cardiac problems, uncontrolled hypertension, malnutrition and severe immune deficiency
capsule, 3g/day, 3 months
Time frame: 3 months
Time frame: 3 months
Jyoti Clinical and Pathological Laboratory
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05929079
Apnea, Body Weight
Anniston, Alabama, United States
View Trial DetailsNCT06649344
Diabetes Mellitus, Diabetes Mellitus, Type 2
Tianjin, Tianjin Municipality, China
View Trial DetailsNCT00038727
Body Weight, CVD
Rockville, Maryland, United States
View Trial DetailsNCT07533539
Diabetes Mellitus, Diabetes Mellitus, Type 2
Seoul, South Korea
View Trial Details